In vitro vancomycin susceptibility amongst methicillin resistant Staphylococcus aureus

Medical Journal Armed Forces India

Volumn 70, Issue 3, 2014, Pages 215-219

  Chaudhari, C N ^a   Tandel, K ^b   Grover, N ^a   Bhatt, P ^a   Sahni, A K ^a   Sen, S ^c   Prahraj, A K ^d  

^a ARMED FORCES MEDICAL COLLEGE   (India)

^b Military Hospital Gwalior   (India)

^c ARMY HOSPITAL RESEARCH AND REFERRAL   (India)

^d ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Agar dilution method; E test (Epsilometer Test); MRSA; Staphylococcus aureus; Vancomycin

Indexed keywords

CEFOXITIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; LINEZOLID; NITROFURANTOIN; NORFLOXACIN; PENICILLIN DERIVATIVE; TETRACYCLINE; VANCOMYCIN;

AGAR DILUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; EPSILOMETER TEST; GEOGRAPHIC DISTRIBUTION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVALENCE; PROSPECTIVE STUDY; TERTIARY CARE CENTER; TEST STRIP;

EID: 84905566263     PISSN: 03771237     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mjafi.2013.11.008     Document Type: Article

References (26)

1. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG. The evolutionary history of methicillin-resistant Staphylococcus aureus(MRSA). Proc Natl Acad Sci USA. 2002; 99(11): 7687.
2. Indian Network for Surveillance of Antimicrobial Resistance (INSAR) Group, India. Methicillin resistant Staphylococcus aureus(MRSA) in India: prevalence & susceptibility pattern. Indian J Med Res. 2013; 137: 363-369.
3. Howden BP, Davies JK, Johnson PDR, Stinear TP, Grayson ML. Reduced vancomycin susceptibility inStaphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010; 23: 99-138.
4. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997; 350: 1670-1673.
5. Tiwari HK, Sen MR. Emergence of vancomycin resistant Staphylococcus aureus(VRSA) from a tertiary care hospital from northern part of India. BMC Infect Dis. 2006; 6: 156-162.
6. Saha B, Singh AK, Ghosh A, Bal M. Identification and characterization of a vancomycin-resistantStaphylococcus aureusisolated from Kolkata (South Asia). J Med Microbiol. 2008; 57: 72-79.
7. Gowrishankar S, Thenmozhi R, Balaji K, Pandian SK. Emergence of methicillin-resistant, vancomycinintermediateStaphylococcus aureusamong patients associated with group A Streptococcal pharyngitis infection in southern India. Infect Genet Evol. 2013; 14: 383-389.
8. Thati V, Shivannavar CT, Gaddad SM. Vancomycin resistance among methicillin resistantStaphylococcus aureusisolates from intensive care units of tertiary care hospitals in Hyderabad. Indian J Med Res. 2011; 134: 704-708.
9. Centers for Disease Control and Prevention. Laboratory capacity to detect antimicrobial resistance, 1998. Morb Mortal Wkly Rep. 2000; 48: 1167-1171.
10. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard. 7th ed. Wayne, PA: CLSI Document M7-A8. CLSI; 2009.
11. EUCAST Guidelines for Detection of Resistance Mechanisms and Specific Resistances of Clinical and/or Epidemiological Importance. Sweden: The European Committee on Antimicrobial Susceptibility Testing; 2012 [cited 2013 May 15]. Available at: www. eucast. org.
12. Hageman JC, Patel JB, Carey RC, Tenover FC, McDonald LC. Investigation and Control of Vancomycin-intermediate and ResistantStaphylococcus aureus; a Guide for Health Departments and Infection Control Personnel. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2006 [cited 2013 May 15]. Available from: http: //www. cdc. gov/ncidod/dhqp/pdf/ar/ visa_vrsa_guide. pdf.
13. Baird D. Staphylococcus: cluster-forming gram-positive cocci. In: Collee JG, Fraser AG, Marmion BP, Simmons A, eds. Mackie & McCartney Practical Medical Microbiology. 14th ed. New Delhi: Elsevier; 2007: 253-261.
14. Kini AR, Shetty V, Kumar AM, Shetty SM, Shetty A. Communityassociated, methicillin-susceptible, and methicillin-resistant Staphylococcus aureusbone and joint infections in children: experience from India. J Pediatr Orthop. 2013; 22: 158-166.
15. Alvarez-Uria G, Reddy R. Prevalence and antibiotic susceptibility of community-associated methicillin-resistant Staphylococcus aureusin a rural area of India: is MRSA replacing methicillin-susceptibleStaphylococcus aureusin the Community? ISRN Dermatol. 2012; 2012: 248951-248955.
16. Tsering DC, Pal R, Kar S. Methicillin-resistantStaphylococcus aureus: prevalence and current susceptibility pattern in Sikkim. J Glob Infect Dis. 2011; 3: 9-13.
17. Falagas ME, Manta KG, Ntziora F, et al. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother. 2006; 58: 273-280.
18. Beekmann SE, Gilbert DN, Polgreen PM. Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey. Diagn Microbiol Infect Dis. 2008; 62: 407-410.
19. Joana S, Pedro P, Elsa G, Filomena M. Is vancomycin MIC creep a worldwide phenomenon? Assessment ofS. aureus vancomycin MIC in a tertiary university hospital. BMC Res Notes. 2013; 6: 65.
20. Kruzel MC, Lewis CT, Welsh CT, et al. Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistantStaphylococcus aureus. J Clin Microbiol. 2011; 49(6): 2272-2273.
21. Tandel K, Praharaj AK, Kumar S. Differences in vancomycin MIC among MRSA isolates by agar dilution and E test method. Ind J Med Microbiol. 2012; 30: 453-455.
22. Hsu DI, Hidayat LK, Quist R, et al. Comparison of methodspecific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistantStaphylococcus aureus(MRSA) infections. Int J Antimicrob Agents. 2008; 32: 378-385.
23. Tenover FC, Moellering Jr RC. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007; 44: 1208-1215.
24. Tiwari S, Sahu M, Rautaraya B, Karuna T, Mishra SR, Bhattacharya S. Prevalence of methicillin-resistant Staphylococcus aureusand its antibiotic susceptibility pattern in a tertiary care hospital. J Indian Med Assoc. 2011; 109: 800-801.
25. Pai V, Rao VI, Rao SP. Prevalence and Antimicrobial susceptibility pattern of methicillin-resistantStaphylococcus aureus[MRSA] isolates at a tertiary care hospital in Mangalore, South India. J Lab Physicians. 2010; 2: 82-84.
26. Goud R, Gupta S, Neogi U, et al. Community prevalence of methicillin and vancomycin resistantStaphylococcus aureusin and around Bangalore, southern India. Rev Soc Bras Med Trop. 2011; 44: 309-312.